Everads Therapy
Business Services · 1-10 Employees
View Company Info for Free
Overview
Phone Number
+972 37684943Website
www.everads-therapy.comRevenue
<$5 MillionIndustry
About Everads Therapy
Everads Therapy Org Chart
Is Everads Therapy your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Everads Therapy has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Everads Therapy
Click to see if Everads Therapy had a recent Job posting/layoffs
Earning: See what the market has to say on Everads Therapy recently announced quarterly report
Check out if Everads Therapy is spiking on competitors!
Funding: Get notified immidiatlly once Everads Therapy has new funding data
Product Launch: Get notified when Everads Therapy launches new products
Everads Therapy, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Recommended Actions
Find VP level buyers at Everads Therapy
Find more new buyers
Company Profile Activity
Activity Insights
Everads Therapy is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Everads Therapy is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Everads Therapy.
Everads Therapy Tech Stack
A closer look at the technologies used by Everads Therapy
Everads Therapy News & Media
Everads Announces Two Oral Presentations at ASRS 2025, Including Full Clinical Trial Results with Its Novel Suprachoroidal Injector
– Clinical study confirms safety, feasibility, and tolerability of the Everads Injector– – Preclinical data demonstrate the feasibility of in-office, minimally invasive suprachoroidal buckling using the Everads Injector to repair retinal detachments – TEL AVIV, Israel, July 30, 2025...Everads Announces Five Abstracts Accepted for Presentation at ARVO 2025, Including First-in-Human Results Using its Novel Suprachoroidal Injector
- Clinical results demonstrate safety, feasibility, and tolerability of the Everads Injector - Additional presentations showcase the broad potential of Everads' platform across gene therapy, small molecules, and suprachoroidal buckling as an innovative approach for the repair of retinal...Everads Presents Clinical Data from First-in-Human Trial of Suprachoroidal Delivery Technology at EURETINA
- 1st cohort data demonstrates safety, feasibility and tolerability of the Everads Injector for delivering drugs to the back of the eye via the suprachoroidal space - Results validate use of the Injector in a clinical, office-based setting, and will support the clinical trial applications...Everads Enters License Agreement with Kriya for Development of Ocular Gene Therapy Candidates Using Everads' Suprachoroidal Delivery Technology
Kriya given field-based exclusivity for use of Everads' platform using gene therapy against certain prespecified therapeutic targets Agreement follows a year-long collaboration between the Parties evaluating Everads' technology for delivery of gene therapy Recent publication in TVST...
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Everads Therapy
Everads is an emerging startup focused on developing novel delivery technology for treating retinal diseases through suprachoroidal administration. Their innovative approach facilitates targeted and rapid delivery of therapies to the choroid and retina, aiming to improve treatment efficacy and reduce patient burden. The company is also building an... Read More